Table 3.
International studies of atrial fibrillation (including Asian/China subgroups)
| Author | Study date | Patients | Ethnicity, n, % | OACs, % | Aspirin, % | Stroke prevalence, % |
| Ohman et al 30 31 | RecordAF, RecordAF-Asia Pacific, with 1 year follow-up April 2009–July 2010 |
n=5604 Mean age 66 years n=2629 Mean age 64 years |
RecordAF-Asia Pacific: Chinese: 951 (36%) Korean: 453 (17%) White: 446 (17%) Thai: 515 (20%) Other: 264 (10%) |
RecordAF: 52% RecordAF-Asia Pacific: 36% |
– | RecordAF: 2.1% RecordAF-Asia Pacific:- |
| Ohman et al 6 | REACH registry, with 4 years outcome 2003–2009 |
n=4582 Mean age 64 years |
– | North America/South America: 59.8% Western Europe/Eastern Europe: 51.8% Asia/Japan/Middle East: 44.6% |
48.9% | 7.7% |
| Oh et al 32 | GARFIELD registry 2010–2013 |
n=17 162 Asia: mean age 61 years Other regions: mean age 71 years |
Other regions of the world: 13 541 (78.9%) Asian: 3621 (21.1%) |
Other regions of the world: 53.3% Asia: 37.8% |
– | – |
| Huisman et al 33 | GLORIA II November 2011–December 2014 |
n=15 092 Mean age 71 years |
Europe: 7108 (47.1%) North America: 3403 (22.5%) Asia: 3071 (20.3%) Latin America: 913 (6.0%) Middle East/Africa: 597 (4.0%) |
Europe: 90.1% North America: 78.4% Asia: 55.2% Latin America: 85.3% Middle East/Africa: 87.4% |
Europe: 6.0% North America: 14.0% Asia: 25.1% Latin America: 10.5% Middle East/Africa: 11.1% |
– |
OAC, oral anticoagulant.